Literature DB >> 33612403

Outcomes of cystic fibrosis pulmonary exacerbations treated with antibiotics with activity against anaerobic bacteria.

Lauren M Castner1, Madsen Zimbric1, Shannon Cahalan1, Corey Powell2, Lindsay J Caverly3.   

Abstract

BACKGROUND: Obligate and facultative anaerobic bacteria are prevalent in cystic fibrosis (CF) airways. Increases in anaerobe relative abundance have been associated with CF pulmonary exacerbations (PEx); however, the impact of antibiotic treatment of anaerobes during PEx is unknown. We hypothesized that PEx treated with antibiotics with activity against anaerobes would improve outcomes compared to antibiotics without anaerobic activity.
METHODS: This was a single-center, retrospective study of people with CF, ages 6 years and older, treated with intravenous (IV) antibiotics for PEx. IV antibiotics were classified as either broad or minimal anaerobic activity. PEx treated with broad anaerobe coverage were propensity-score matched to PEx treated with minimal anaerobic coverage. The primary outcome, % of baseline % predicted forced expiratory volume in one second (ppFEV1) recovered, was compared between antibiotic categories with a linear mixed model. The secondary outcome, time to next PEx, was assessed using a Prentice Williams Petersen model.
RESULTS: 514 PEx from 182 patients were included. Broad anaerobe coverage was used in 27% of PEx, and was used more often for older patients (p < 0.001) with worse baseline ppFEV1 (p < 0.001), and with Achromobacter (p < 0.001) or Burkholderia infections (p = 0.002). In the matched PEx, broad anaerobe coverage was not a significant predictor of % of baseline ppFEV1 recovered (∆ppFEV1 = -2.4, p = 0.09). Broad anaerobe coverage was also not a significant predictor of time to next PEx (HR 0.89, 95% CI 0.7-1.13, p = 0.35).
CONCLUSIONS: In this single center, retrospective study, antibiotics with broad activity against anaerobes were not associated with improved outcomes of CF PEx.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Anaerobes; Antibiotics; Exacerbations

Mesh:

Substances:

Year:  2021        PMID: 33612403      PMCID: PMC8371065          DOI: 10.1016/j.jcf.2021.02.001

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  30 in total

1.  Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerin L Tyrrell; Helen T Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

2.  Supporting information retrieval from electronic health records: A report of University of Michigan's nine-year experience in developing and using the Electronic Medical Record Search Engine (EMERSE).

Authors:  David A Hanauer; Qiaozhu Mei; James Law; Ritu Khanna; Kai Zheng
Journal:  J Biomed Inform       Date:  2015-05-13       Impact factor: 6.317

3.  Airway microbiota across age and disease spectrum in cystic fibrosis.

Authors:  Edith T Zemanick; Brandie D Wagner; Charles E Robertson; Richard C Ahrens; James F Chmiel; John P Clancy; Ronald L Gibson; William T Harris; Geoffrey Kurland; Theresa A Laguna; Susanna A McColley; Karen McCoy; George Retsch-Bogart; Kurtis T Sobush; Pamela L Zeitlin; Mark J Stevens; Frank J Accurso; Scott D Sagel; J Kirk Harris
Journal:  Eur Respir J       Date:  2017-11-16       Impact factor: 16.671

4.  Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.

Authors:  Sonya L Heltshe; Christopher H Goss; Valeria Thompson; Scott D Sagel; Don B Sanders; Bruce C Marshall; Patrick A Flume
Journal:  Thorax       Date:  2015-04-24       Impact factor: 9.139

5.  The Role of Short-Chain Fatty Acids, Produced by Anaerobic Bacteria, in the Cystic Fibrosis Airway.

Authors:  Bojana Mirković; Michelle A Murray; Gillian M Lavelle; Kevin Molloy; Ahmed Abdul Azim; Cedric Gunaratnam; Fiona Healy; Dubhfeasa Slattery; Paul McNally; Joe Hatch; Matthew Wolfgang; Michael M Tunney; Marianne S Muhlebach; Rosaleen Devery; Catherine M Greene; Noel G McElvaney
Journal:  Am J Respir Crit Care Med       Date:  2015-12-01       Impact factor: 21.405

Review 6.  Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations.

Authors:  Patrick A Flume; Peter J Mogayzel; Karen A Robinson; Christopher H Goss; Randall L Rosenblatt; Robert J Kuhn; Bruce C Marshall
Journal:  Am J Respir Crit Care Med       Date:  2009-09-03       Impact factor: 21.405

7.  Maintenance tobramycin primarily affects untargeted bacteria in the CF sputum microbiome.

Authors:  Maria T Nelson; Daniel J Wolter; Alexander Eng; Eli J Weiss; Anh T Vo; Mitchell J Brittnacher; Hillary S Hayden; Sumedha Ravishankar; Gilbert Bautista; Anina Ratjen; Marcella Blackledge; Sharon McNamara; Laura Nay; Cheryl Majors; Samuel I Miller; Elhanan Borenstein; Richard H Simon; John J LiPuma; Luke R Hoffman
Journal:  Thorax       Date:  2020-07-06       Impact factor: 9.139

8.  Lung microbiota across age and disease stage in cystic fibrosis.

Authors:  Bryan Coburn; Pauline W Wang; Julio Diaz Caballero; Shawn T Clark; Vijaya Brahma; Sylva Donaldson; Yu Zhang; Anu Surendra; Yunchen Gong; D Elizabeth Tullis; Yvonne C W Yau; Valerie J Waters; David M Hwang; David S Guttman
Journal:  Sci Rep       Date:  2015-05-14       Impact factor: 4.379

9.  The effects of inhaled aztreonam on the cystic fibrosis lung microbiome.

Authors:  Alya A Heirali; Matthew L Workentine; Nicole Acosta; Ali Poonja; Douglas G Storey; Ranjani Somayaji; Harvey R Rabin; Fiona J Whelan; Michael G Surette; Michael D Parkins
Journal:  Microbiome       Date:  2017-05-05       Impact factor: 14.650

10.  Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis.

Authors:  Lisa A Carmody; Lindsay J Caverly; Bridget K Foster; Mary A M Rogers; Linda M Kalikin; Richard H Simon; Donald R VanDevanter; John J LiPuma
Journal:  PLoS One       Date:  2018-03-09       Impact factor: 3.240

View more
  1 in total

1.  Multi-Omics Study of Keystone Species in a Cystic Fibrosis Microbiome.

Authors:  Cynthia B Silveira; Ana G Cobián-Güemes; Carla Uranga; Jonathon L Baker; Anna Edlund; Forest Rohwer; Douglas Conrad
Journal:  Int J Mol Sci       Date:  2021-11-07       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.